Sex Differences in the Systemic and Local Immune Response of Pancreatic Cancer Patients.
CXCL12
pancreatic cancer
pancreatic ductal adenocarcinoma
sex difference
tumor immunology
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
17 Mar 2023
17 Mar 2023
Historique:
received:
10
01
2023
revised:
01
03
2023
accepted:
14
03
2023
medline:
30
3
2023
entrez:
29
3
2023
pubmed:
30
3
2023
Statut:
epublish
Résumé
Mounting evidence suggests that sex plays a critical role in various aspects of cancer such as immune responses. However, a male bias exists in human and non-human studies including immunotherapy trials. The role of sex on immune responses in pancreatic ductal adenocarcinoma (PDA) is unclear. Here, tumor tissues (tumor and stroma separately) and corresponding blood samples from patients with PDA ( Females showed a stronger systemic immune response with higher levels of CXCL9, IL1B, IL6, IL10 and IL13. Additionally, more peripheral white blood cells were detected in females. In the microenvironment, males showed higher tumoral levels of CXCL12. No differences were detected in the stroma. Females showed a tendency towards an anti-tumoral immune cell profile. CXCL12 blockade indicated a differential microenvironmental effect by sex in an independent immunotherapy trial cohort of patients with PDA (one female, five males). The overall survival did not differ by sex in our cohort. Systemic and local immune responses differ between sexes in PDA. Accordingly, sex-dependent differences need to be considered in human studies and for specific immunological interventions before clinical translation.
Sections du résumé
BACKGROUND
BACKGROUND
Mounting evidence suggests that sex plays a critical role in various aspects of cancer such as immune responses. However, a male bias exists in human and non-human studies including immunotherapy trials. The role of sex on immune responses in pancreatic ductal adenocarcinoma (PDA) is unclear.
METHODS
METHODS
Here, tumor tissues (tumor and stroma separately) and corresponding blood samples from patients with PDA (
RESULTS
RESULTS
Females showed a stronger systemic immune response with higher levels of CXCL9, IL1B, IL6, IL10 and IL13. Additionally, more peripheral white blood cells were detected in females. In the microenvironment, males showed higher tumoral levels of CXCL12. No differences were detected in the stroma. Females showed a tendency towards an anti-tumoral immune cell profile. CXCL12 blockade indicated a differential microenvironmental effect by sex in an independent immunotherapy trial cohort of patients with PDA (one female, five males). The overall survival did not differ by sex in our cohort.
CONCLUSION
CONCLUSIONS
Systemic and local immune responses differ between sexes in PDA. Accordingly, sex-dependent differences need to be considered in human studies and for specific immunological interventions before clinical translation.
Identifiants
pubmed: 36980700
pii: cancers15061815
doi: 10.3390/cancers15061815
pmc: PMC10047039
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : RR Pohl Stiftung
ID : X
Références
Lancet. 2019 Jun 15;393(10189):2440-2454
pubmed: 31155275
Biol Lett. 2019 May 31;15(5):20190174
pubmed: 31113309
Front Oncol. 2022 Mar 24;12:839779
pubmed: 35402271
Neoplasia. 2022 Jun;28:100789
pubmed: 35395492
Res Integr Peer Rev. 2016 May 03;1:2
pubmed: 29451543
Gut. 2023 Feb;72(2):325-337
pubmed: 35705369
Front Oncol. 2020 Nov 23;10:597788
pubmed: 33330090
Nature. 2014 Jun 19;510(7505):340
pubmed: 24943947
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Br J Cancer. 2020 Feb;122(3):333-339
pubmed: 31787751
Semin Cancer Biol. 2022 Nov;86(Pt 3):166-179
pubmed: 35278635
Int J Immunopharmacol. 1988;10(1):15-22
pubmed: 3366506
Front Immunol. 2018 Aug 27;9:1931
pubmed: 30210492
Blood. 2008 Dec 1;112(12):4574-84
pubmed: 18802009
Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20212-7
pubmed: 24277834
Gut. 2018 Feb;67(2):320-332
pubmed: 27797936
Oncoimmunology. 2021 Aug 10;10(1):1962135
pubmed: 34408923
Front Oncol. 2021 Aug 30;11:710286
pubmed: 34527583
Br J Pharmacol. 2019 Nov;176(21):4107-4118
pubmed: 30418665
J Immunol. 2004 Feb 1;172(3):1426-36
pubmed: 14734718
Ann N Y Acad Sci. 1999 Jun 22;876:426-9
pubmed: 10415638
Nat Biotechnol. 2020 Jun;38(6):675-678
pubmed: 32444850
Proc Natl Acad Sci U S A. 2014 Jan 14;111(2):869-74
pubmed: 24367114
Cell Immunol. 2012;272(2):214-9
pubmed: 22078320
Nat Rev Immunol. 2016 Oct;16(10):626-38
pubmed: 27546235
Biol Reprod. 2008 Mar;78(3):432-7
pubmed: 18003947
Sci Immunol. 2022 Jul 22;7(73):eabq6509
pubmed: 35867802
Immunity. 2019 Jun 18;50(6):1498-1512.e5
pubmed: 31097342
J Int Med Res. 2018 Dec;46(12):5228-5236
pubmed: 30304975
J Immunother Cancer. 2021 Oct;9(10):
pubmed: 34607895
Science. 2015 Apr 3;348(6230):74-80
pubmed: 25838376
Cancer Cell. 2016 Apr 11;29(4):587-601
pubmed: 27070705
BMC Med Genomics. 2022 Apr 25;15(1):96
pubmed: 35468838
Trends Cancer. 2022 Apr;8(4):303-315
pubmed: 35190302
Biol Sex Differ. 2020 Apr 15;11(1):17
pubmed: 32295632
Front Immunol. 2018 Jun 04;9:1269
pubmed: 29915601
Oncoimmunology. 2022 Jan 31;11(1):2027148
pubmed: 35127251
Int J Mol Sci. 2021 Mar 15;22(6):
pubmed: 33804263
Molecules. 2019 Sep 04;24(18):
pubmed: 31487832
Nat Rev Immunol. 2008 Sep;8(9):737-44
pubmed: 18728636
Neurosci Biobehav Rev. 2011 Jan;35(3):565-72
pubmed: 20620164
Cancer Res. 2018 Apr 1;78(7):1700-1712
pubmed: 29363544
Front Immunol. 2019 May 09;10:1076
pubmed: 31156632
Cancer Epidemiol Biomarkers Prev. 2020 Jul;29(7):1389-1397
pubmed: 32349967